Alicia Grande Sells 90,000 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRXGet Rating) CFO Alicia Grande sold 90,000 shares of the company’s stock in a transaction dated Friday, September 16th. The shares were sold at an average price of $13.50, for a total transaction of $1,215,000.00. Following the completion of the transaction, the chief financial officer now directly owns 267,442 shares of the company’s stock, valued at $3,610,467. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Alicia Grande also recently made the following trade(s):

  • On Wednesday, September 14th, Alicia Grande sold 50,000 shares of Catalyst Pharmaceuticals stock. The shares were sold at an average price of $15.57, for a total transaction of $778,500.00.
  • On Monday, August 29th, Alicia Grande sold 57,000 shares of Catalyst Pharmaceuticals stock. The shares were sold at an average price of $14.20, for a total transaction of $809,400.00.
  • On Friday, August 26th, Alicia Grande sold 11,095 shares of Catalyst Pharmaceuticals stock. The shares were sold at an average price of $14.40, for a total transaction of $159,768.00.
  • On Wednesday, August 17th, Alicia Grande sold 130,741 shares of Catalyst Pharmaceuticals stock. The stock was sold at an average price of $13.86, for a total transaction of $1,812,070.26.

Catalyst Pharmaceuticals Trading Down 2.7 %

Catalyst Pharmaceuticals stock opened at $12.46 on Thursday. The company has a market capitalization of $1.28 billion, a P/E ratio of 24.43 and a beta of 1.31. The firm’s fifty day simple moving average is $12.49 and its 200-day simple moving average is $9.21. Catalyst Pharmaceuticals, Inc. has a 1-year low of $4.85 and a 1-year high of $17.22.

Analysts Set New Price Targets

Several equities analysts have recently commented on CPRX shares. Roth Capital cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and increased their price target for the stock from $10.00 to $15.50 in a research report on Wednesday, August 24th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday, August 8th. HC Wainwright raised their price target on shares of Catalyst Pharmaceuticals from $12.00 to $18.00 and gave the company a “buy” rating in a research note on Thursday, August 11th. Finally, Truist Financial raised their price objective on shares of Catalyst Pharmaceuticals from $12.00 to $17.00 and gave the company a “buy” rating in a research note on Thursday, August 11th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Catalyst Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $14.81.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CPRX. FMR LLC raised its holdings in Catalyst Pharmaceuticals by 24.2% in the 2nd quarter. FMR LLC now owns 4,218 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 822 shares during the period. Point72 Hong Kong Ltd raised its holdings in Catalyst Pharmaceuticals by 84.3% in the 4th quarter. Point72 Hong Kong Ltd now owns 5,932 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 2,713 shares during the period. Covestor Ltd raised its holdings in Catalyst Pharmaceuticals by 768.0% in the 1st quarter. Covestor Ltd now owns 4,878 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 4,316 shares during the period. Quantbot Technologies LP bought a new position in Catalyst Pharmaceuticals in the 1st quarter worth $62,000. Finally, Quantamental Technologies LLC bought a new position in Catalyst Pharmaceuticals in the 2nd quarter worth $72,000. Institutional investors own 74.16% of the company’s stock.

About Catalyst Pharmaceuticals

(Get Rating)

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

See Also

Insider Buying and Selling by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.